A Phase 1b/2a clinical study of SACT-1 in neuroblastoma patients
Latest Information Update: 23 Jun 2023
At a glance
- Drugs SACT 1 (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Sponsors Aptorum Group
Most Recent Events
- 22 Jun 2023 According to Aptorum media release, the company announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA.
- 03 Mar 2023 According to Aptorum media release, FDA has generally agreed on proposed clinical development plan for this study.
- 03 Mar 2023 According to Aptorum media release, company has announced the completion of an end of phase I (EOP1) meeting with the US Food and Drug Administration.